SCHEMBL4665828

SCHEMBL4665828

CCN(CC)CCn1ccc2cc(-c3cc(Nc4ccc(N(OC=O)S(=O)(=O)c5ccc(F)cc5)cc4)ncn3)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 13/20 0.46
SCN9A Q15858 1/20 0.45
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
GLA P06280 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
HTR6 P50406 2/20 0.41
BPTF Q12830 2/20 0.37
ABL1 P00519 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4665765 0.96 EGFR (0.42) EGFRSCN9AMEN1USP2ALDH1A1
SCHEMBL4664380 0.95 EGFR (0.41) EGFRSCN9AMEN1USP2ALDH1A1
SCHEMBL4667458 0.94 HTR6 (0.41) EGFRSCN9AMEN1USP2ALDH1A1
SCHEMBL4664313 0.93 HTR6 (0.42) EGFRSCN9AHTR6BPTFABL1
SCHEMBL4665715 0.92 EGFR (0.43) EGFRSCN9AMEN1USP2ALDH1A1
SCHEMBL4666112 0.91 EGFR (0.39) EGFRSCN9AMEN1USP2ALDH1A1
SCHEMBL4667420 0.91 EGFR (0.39) EGFRSCN9AMEN1USP2ALDH1A1
SCHEMBL4666211 0.90 BPTF (0.40) EGFRSCN9AMEN1USP2ALDH1A1
SCHEMBL4665826 0.90 HTR6 (0.41) EGFRSCN9AMEN1USP2ALDH1A1
SCHEMBL4664243 0.90 HTR6 (0.42) EGFRSCN9AMEN1USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 EGFR 279/4885SCN9A 1693/4885MEN1 3892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.